Ziopharm’s RPM CD19 CAR-T Ph1 Trial in Taiwan Paused; Clinical Programs Continue to Face Delays; Ziopharm Q2 2021 Earnings Call Summary
On Monday, August 9, Ziopharm held their Q2 2021 earnings call (press release / presentation) highlighting that their TCR-T Library program is anticipated to dose the first patient in Q4 2021. Furthermore, management disclosed that their RPM CD19 CAR-T Ph1 trial for lymphoid malignancies in Taiwan will be paused until the manufacturing process is optimized. Below, Celltelligence provides insights on how Ziopharm’s manufacturing strategy may strengthen their TCR-T Library program while discussing the significance of their RPM CD19 CAR-T program delay.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.